Share on StockTwits

Equities researchers at Dawson James initiated coverage on shares of Neogenomics (NYSE:NEO) in a research report issued on Wednesday, StockRatingsNetwork reports. The firm set a “buy” rating and a $6.00 price target on the stock. Dawson James’ price target indicates a potential upside of 81.27% from the company’s current price.

A number of other analysts have also recently weighed in on NEO. Analysts at Longbow Research initiated coverage on shares of Neogenomics in a research note on Monday. They set a “buy” rating and a $6.00 price target on the stock. Separately, analysts at Roth Capital initiated coverage on shares of Neogenomics in a research note on Monday. They set a “buy” rating and a $6.00 price target on the stock. Finally, analysts at Stephens initiated coverage on shares of Neogenomics in a research note on Friday, February 14th. They set an “overweight” rating and a $6.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $6.20.

Shares of Neogenomics (NYSE:NEO) traded down 1.81% on Wednesday, hitting $3.25. The stock had a trading volume of 228,848 shares. Neogenomics has a 52-week low of $2.05 and a 52-week high of $4.69. The stock has a 50-day moving average of $3.32 and a 200-day moving average of $3.61. The company has a market cap of $160.2 million and a P/E ratio of 80.73.

Neogenomics (NYSE:NEO) last announced its earnings results on Wednesday, February 19th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.02. The company had revenue of $18.30 million for the quarter, compared to the consensus estimate of $17.80 million. On average, analysts predict that Neogenomics will post $0.03 earnings per share for the current fiscal year.

NeoGenomics, Inc (NYSE:NEO) operates a network of cancer-focused testing laboratories.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.